$VNDA
Vanda Pharmaceuticals Inc.

2019 Form 10-K Financial Statement

#000134717820000003 Filed on February 26, 2020

View on sec.gov

Income Statement

Concept 2019 2018 Q4 2018 Q3
Revenue $227.2M $53.04M $49.14M
YoY Change 17.64% 19.8% 18.87%
Cost Of Revenue $24.49M $5.670M $5.068M
YoY Change 19.41% 18.37% 12.0%
Gross Profit $202.7M $46.99M $43.67M
YoY Change 17.43% 20.33% 20.04%
Gross Profit Margin 89.22% 88.6% 88.88%
Selling, General & Admin $129.7M $24.92M $26.05M
YoY Change 22.68% -19.74% -16.31%
% of Gross Profit 64.0% 53.03% 59.65%
Research & Development $48.65M $12.92M $11.39M
YoY Change 11.6% 27.29% 11.91%
% of Gross Profit 24.0% 27.49% 26.08%
Depreciation & Amortization $1.400M $700.0K $700.0K
YoY Change 0.0% -12.5% 0.0%
% of Gross Profit 0.69% 1.49% 1.6%
Operating Expenses $178.4M $38.22M $37.44M
YoY Change 19.44% -8.21% -9.36%
Operating Profit $22.81M $9.150M $6.233M
YoY Change 4.93% -525.58% -226.61%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $6.200M $1.170M $1.030M
YoY Change 72.22% 192.5% 157.5%
Pretax Income $29.03M $10.32M $7.263M
YoY Change 15.54% -689.71% -260.44%
Income Tax -$86.53M -$40.00K $100.0K
% Of Pretax Income -298.07% -0.39% 1.38%
Net Earnings $115.6M $10.36M $7.171M
YoY Change 358.4% -663.66% -257.6%
Net Earnings / Revenue 50.86% 19.53% 14.59%
Basic Earnings Per Share $2.17 $0.20 $0.14
Diluted Earnings Per Share $2.11 $0.19 $0.13
COMMON SHARES
Basic Shares Outstanding 53.14M shares 52.45M shares 52.39M shares
Diluted Shares Outstanding 54.85M shares 54.71M shares

Balance Sheet

Concept 2019 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $312.1M $257.4M $240.6M
YoY Change 21.25% 79.45% 71.99%
Cash & Equivalents $45.10M $61.01M $60.78M
Short-Term Investments $267.1M $196.4M $179.8M
Other Short-Term Assets $14.50M $12.00M $12.10M
YoY Change 20.83% 342.48% 340.48%
Inventory $1.100M $994.0K $887.0K
Prepaid Expenses
Receivables $26.40M $28.78M $25.26M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $354.1M $299.1M $278.8M
YoY Change 18.39% 76.11% 64.28%
LONG-TERM ASSETS
Property, Plant & Equipment $15.00M $4.417M $4.579M
YoY Change 240.91% -16.75% -15.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $91.50M $4.000M $3.600M
YoY Change 2187.5% -4.76% -10.0%
Total Long-Term Assets $129.6M $33.00M $33.13M
YoY Change 292.73% -7.23% -7.94%
TOTAL ASSETS
Total Short-Term Assets $354.1M $299.1M $278.8M
Total Long-Term Assets $129.6M $33.00M $33.13M
Total Assets $483.7M $332.1M $311.9M
YoY Change 45.65% 61.68% 51.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.900M $5.200M $4.800M
YoY Change 13.46% 18.18% 33.33%
Accrued Expenses $53.60M $47.60M $41.50M
YoY Change 12.61% 22.05% 1.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $59.50M $53.02M $46.24M
YoY Change 12.26% -24.66% -35.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $13.30M $3.693M $4.278M
YoY Change 259.46% 0.49% 15.59%
Total Long-Term Liabilities $13.30M $3.693M $4.278M
YoY Change 259.46% 0.49% 15.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $59.50M $53.02M $46.24M
Total Long-Term Liabilities $13.30M $3.693M $4.278M
Total Liabilities $72.80M $56.71M $50.52M
YoY Change 28.4% -23.41% -32.85%
SHAREHOLDERS EQUITY
Retained Earnings -$336.2M -$346.6M
YoY Change -6.97% -3.62%
Common Stock $611.6M $607.9M
YoY Change 24.1% 24.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $410.9M $275.4M $261.4M
YoY Change
Total Liabilities & Shareholders Equity $483.7M $332.1M $311.9M
YoY Change 45.65% 61.68% 51.64%

Cashflow Statement

Concept 2019 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income $115.6M $10.36M $7.171M
YoY Change 358.4% -663.66% -257.6%
Depreciation, Depletion And Amortization $1.400M $700.0K $700.0K
YoY Change 0.0% -12.5% 0.0%
Cash From Operating Activities $45.95M $15.30M $8.700M
YoY Change 53.23% 350.0% 295.45%
INVESTING ACTIVITIES
Capital Expenditures $1.019M -$100.0K -$100.0K
YoY Change 176.9% -50.0% -75.0%
Acquisitions
YoY Change
Other Investing Activities -$67.30M -$15.80M -$8.800M
YoY Change -20.17% -310.67% -251.72%
Cash From Investing Activities -$68.31M -$15.80M -$8.900M
YoY Change -37.71% -313.51% -264.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.264M 800.0K 100.0K
YoY Change -94.15% 700.0% -87.5%
NET CHANGE
Cash From Operating Activities $45.95M 15.30M 8.700M
Cash From Investing Activities -$68.31M -15.80M -8.900M
Cash From Financing Activities $6.264M 800.0K 100.0K
Net Change In Cash -$16.10M 300.0K -100.0K
YoY Change -158.73% -97.25% -101.19%
FREE CASH FLOW
Cash From Operating Activities $45.95M $15.30M $8.700M
Capital Expenditures $1.019M -$100.0K -$100.0K
Free Cash Flow $44.93M $15.40M $8.800M
YoY Change 51.69% 327.78% 238.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001347178
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52477593 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53549612 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52477593 shares
CY2019 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2019 dei Entity Small Business
EntitySmallBusiness
false
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019Q2 dei Entity Public Float
EntityPublicFloat
731200000 USD
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53648617 shares
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity File Number
EntityFileNumber
001-34186
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Registrant Name
EntityRegistrantName
VANDA PHARMACEUTICALS INC.
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
03-0491827
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Pennsylvania Avenue NW
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20037
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300 E
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53549612 shares
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Washington
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
DC
CY2019 dei City Area Code
CityAreaCode
202
CY2019 dei Local Phone Number
LocalPhoneNumber
734-3400
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
27590000 USD
CY2019Q4 us-gaap Assets
Assets
483748000 USD
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2019 dei Trading Symbol
TradingSymbol
VNDA
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45072000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61005000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
267057000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
196355000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26367000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28780000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
1140000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
994000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14500000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11998000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
354136000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
299132000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3864000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4417000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11180000 USD
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
23037000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
24542000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
87680000 USD
CY2018Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0 USD
CY2019Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
3851000 USD
CY2018Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
4039000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
249000 USD
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
165083000 USD
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
105751000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000 USD
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
123841000 USD
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1505000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220665000 USD
CY2018Q4 us-gaap Assets
Assets
332130000 USD
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1527000 USD
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1750000 USD
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
21584000 USD
CY2019Q4 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
31915000 USD
CY2018Q4 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
31231000 USD
CY2019Q4 vnda Milestone Obligation Under License Agreement Current
MilestoneObligationUnderLicenseAgreementCurrent
0 USD
CY2018Q4 vnda Milestone Obligation Under License Agreement Current
MilestoneObligationUnderLicenseAgreementCurrent
200000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
59505000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53015000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12455000 USD
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
843000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3693000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
72803000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
56708000 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
54000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
52000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
631307000 USD
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
611587000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-336218000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
410945000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
275422000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
483748000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
332130000 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
227188000 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
193118000 USD
CY2019 us-gaap Revenues
Revenues
227188000 USD
CY2018 us-gaap Revenues
Revenues
193118000 USD
CY2017 us-gaap Revenues
Revenues
165083000 USD
CY2019 us-gaap Cost Of Goods Sold Excluding Depreciation Depletion And Amortization
CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization
24488000 USD
CY2018 us-gaap Cost Of Goods Sold Excluding Depreciation Depletion And Amortization
CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization
20508000 USD
CY2017 us-gaap Cost Of Goods Sold Excluding Depreciation Depletion And Amortization
CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization
17848000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48649000 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43594000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38547000 USD
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.11
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
129736000 USD
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2019 us-gaap Net Income Loss
NetIncomeLoss
115553000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
25208000 USD
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53045257 shares
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44735146 shares
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-15567000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
248000 USD
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
35000 USD
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.17
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.50
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
204378000 USD
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
171380000 USD
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
181986000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
22810000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
21738000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-16903000 USD
CY2019 us-gaap Other Income
OtherIncome
6218000 USD
CY2018 us-gaap Other Income
OtherIncome
3608000 USD
CY2017 us-gaap Other Income
OtherIncome
1472000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
29028000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
25346000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-15431000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-86525000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
138000 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
136000 USD
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53137562 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50859947 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44735146 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54847060 shares
CY2019 us-gaap Net Income Loss
NetIncomeLoss
115553000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
25208000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-15567000 USD
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
6000 USD
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-22000 USD
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
30000 USD
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
313000 USD
CY2018 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
57000 USD
CY2017 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-122000 USD
CY2019 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
71000 USD
CY2018 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
CY2017 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
10465000 USD
CY2019 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3099000 USD
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-92000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
115553000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
25208000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-15567000 USD
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2525000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
115801000 USD
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
25243000 USD
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15659000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
131330000 USD
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5251000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10465000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-15567000 USD
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-92000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
131387000 USD
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100870000 USD
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6256000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11666000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
25208000 USD
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
35000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
275422000 USD
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6264000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13458000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
115553000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
248000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
410945000 USD
CY2019 us-gaap Depreciation
Depreciation
1387000 USD
CY2018 us-gaap Depreciation
Depreciation
1429000 USD
CY2017 us-gaap Depreciation
Depreciation
1234000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
13458000 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
11666000 USD
CY2018 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
2221000 USD
CY2017 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
426000 USD
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1505000 USD
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1527000 USD
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1750000 USD
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-87767000 USD
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1785000 USD
CY2018 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-167000 USD
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-587000 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2342000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-68309000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-109660000 USD
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11207000 USD
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
394517000 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27414000 USD
CY2019 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2018 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
25000000 USD
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6921000 USD
CY2017 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1019000 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
368000 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1664000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2764000 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4258000 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3652000 USD
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
722000 USD
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-70000 USD
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1060000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3508000 USD
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-618000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5953000 USD
CY2019 vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
761000 USD
CY2018 vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
8223000 USD
CY2017 vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
-11096000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
45947000 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
29986000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1983000 USD
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
282395000 USD
CY2017 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
148135000 USD
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
327227000 USD
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
198103000 USD
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
139568000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10231000 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100870000 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6264000 USD
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6256000 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5251000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6264000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
107126000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5251000 USD
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000 USD
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-38000 USD
CY2017 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16099000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61749000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34335000 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41256000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45650000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61749000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34335000 USD
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2019 vnda Number Of Products In Portfolio
NumberOfProductsInPortfolio
2 product
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-top:8px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.</span></div>
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
274027000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45072000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61005000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45650000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61749000 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
227188000 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
193118000 USD
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
165083000 USD
CY2018Q1 vnda Percentage Of Responsibility For Patients Cost Of Branded Prescription Under Medicare Part D
PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD
0.50
CY2018Q1 vnda Percentage Of Responsibility For Patients Cost Of Branded Prescription Under Medicare Part D
PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD
0.50
vnda Percentage Of Responsibility For Patients Cost Of Branded Prescription Under Medicare Part D
PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD
0.70
CY2019 us-gaap Advertising Expense
AdvertisingExpense
3200000 USD
CY2018 us-gaap Advertising Expense
AdvertisingExpense
900000 USD
CY2017 us-gaap Advertising Expense
AdvertisingExpense
1300000 USD
CY2019 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
196355000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2924000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 USD
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
48000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1140000 USD
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
946000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
1140000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
994000 USD
CY2019Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
659000 USD
CY2018Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
86000 USD
CY2019Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
1109000 USD
CY2018Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
2290000 USD
CY2019Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
1056000 USD
CY2018Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
516000 USD
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
2824000 USD
CY2018Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
2892000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10476000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9636000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6612000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5219000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3864000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4417000 USD
CY2019 us-gaap Depreciation
Depreciation
1400000 USD
CY2018 us-gaap Depreciation
Depreciation
1400000 USD
CY2017 us-gaap Depreciation
Depreciation
1200000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11180000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2147000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12455000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
14602000 USD
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y1M6D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
2300000 USD
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
400000 USD
CY2019 vnda Operating Lease Non Lease Component Expense
OperatingLeaseNonLeaseComponentExpense
1400000 USD
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3600000 USD
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3200000 USD
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
2500000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2326000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2332000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2355000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2420000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2488000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
8182000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
20103000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5501000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
14602000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2147000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12455000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
22757000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2483000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2495000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2335000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2355000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2420000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
10669000 USD
CY2018Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
5593000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5376000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6597000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6363000 USD
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5904000 USD
CY2018Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5172000 USD
CY2019Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
5893000 USD
CY2019 vnda Share Based Compensation Arrangementby Share Based Payment Annual Award Vesting Period Employeesand New Directors
ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors
P4Y
CY2019 vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2147000 USD
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1673000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1532000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
27590000 USD
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
21584000 USD
CY2019 vnda Percentage Of Future Sublicense Fees Payable
PercentageOfFutureSublicenseFeesPayable
mid-twenties
CY2019 vnda Agreements For Clinical And Marketing Services Termination Notice Period
AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod
P90D
CY2019Q4 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
9200000 USD
CY2019Q4 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
1000000.0 USD
CY2019Q4 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
500000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
13000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
7000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
236000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-6000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
249000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000 USD
CY2019 vnda Share Based Compensation Option Awards Contractual Term
ShareBasedCompensationOptionAwardsContractualTerm
P10Y
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
1405000 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5300000 USD
CY2019 vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75
CY2019 vnda Sharebased Compensation Arrangementby Share Based Payment Award Options Vesting Period Number Of Equal Monthly Installments
SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments
36 installment
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.19
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.66
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.81
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6300000 USD
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6300000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13458000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11666000 USD
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10465000 USD
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.58
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.58
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.57
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M12D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M20D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0226
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0268
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0197
CY2019 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2019 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2019 vnda Defined Contribution Plan Vesting Period
DefinedContributionPlanVestingPeriod
P4Y
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000 USD
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000 USD
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
28794000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
25123000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-15693000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
234000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
223000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
262000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
29028000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
25346000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-15431000 USD
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1161000 USD
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
53000 USD
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
65000 USD
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
81000 USD
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
99000 USD
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-66000 USD
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-85624000 USD
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2127000 USD
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-16000 USD
CY2018 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-14000 USD
CY2017 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
137000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-86525000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
138000 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
136000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.018
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.017
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.017
CY2019 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Rate
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActRate
0
CY2018 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Rate
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActRate
0
CY2017 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Rate
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActRate
-2.626
CY2019 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Of2017 Change In Valuation Allowance
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActOf2017ChangeInValuationAllowance
0
CY2018 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Of2017 Change In Valuation Allowance
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActOf2017ChangeInValuationAllowance
0
CY2017 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Of2017 Change In Valuation Allowance
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActOf2017ChangeInValuationAllowance
2.626
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.007
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.026
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3.576
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.164
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.478
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.109
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.091
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.090
CY2019 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
0.171
CY2018 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
-0.027
CY2017 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
0.063
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.027
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.031
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.081
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.005
CY2019 vnda Effective Income Tax Rate Reconciliation Effective Tax Rate Adjustment
EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
0
CY2018 vnda Effective Income Tax Rate Reconciliation Effective Tax Rate Adjustment
EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
0.059
CY2017 vnda Effective Income Tax Rate Reconciliation Effective Tax Rate Adjustment
EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
0.051
CY2019 vnda Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
0.263
CY2018 vnda Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
0
CY2017 vnda Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.010
CY2018 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.039
CY2017 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.130
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.030
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.016
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.027
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-2.981
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.009
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
52034000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
55742000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
5298000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
5202000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2101000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2096000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
1468000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
1247000 USD
CY2019Q4 vnda Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
36041000 USD
CY2018Q4 vnda Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
48066000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
1301000 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
98243000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
113758000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1994000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1247000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
414000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
576000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2408000 USD
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1823000 USD
CY2019Q4 vnda Deferred Tax Assets Liabilities Before Valuation Allowance Net
DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet
95835000 USD
CY2018Q4 vnda Deferred Tax Assets Liabilities Before Valuation Allowance Net
DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet
111935000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8155000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
111950000 USD
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
87680000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
15000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
111950000 USD
CY2019 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
0 USD
CY2019 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
103795000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8155000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
116110000 USD
CY2018 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
4036000 USD
CY2018 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
8196000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
111950000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
146012000 USD
CY2017 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
12403000 USD
CY2017 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
42305000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
116110000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12000000.0 USD
CY2019 vnda Operating Loss Carryforwards Beginning Expiration Year
OperatingLossCarryforwardsBeginningExpirationYear
2031
CY2019 vnda Research And Development Credit Beginning Expiration Year
ResearchAndDevelopmentCreditBeginningExpirationYear
2024
CY2019 vnda Orphan Drug Credit Beginning Expiration Year
OrphanDrugCreditBeginningExpirationYear
2030
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
8700000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
8223000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1518000 USD
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9741000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
9700000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
115553000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
25208000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-15567000 USD
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53137562 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50859947 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44735146 shares
CY2019 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1709498 shares
CY2018 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2185310 shares
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54847060 shares
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53045257 shares
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44735146 shares
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.17
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.50
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2019Q2 us-gaap Revenues
Revenues
59060000 USD
CY2019Q3 us-gaap Revenues
Revenues
59485000 USD
CY2019Q4 us-gaap Revenues
Revenues
60930000 USD
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.11
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1932024 shares
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
903265 shares
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3136515 shares
CY2019Q1 us-gaap Revenues
Revenues
47713000 USD
CY2019Q1 us-gaap Gross Profit
GrossProfit
42220000 USD
CY2019Q2 us-gaap Gross Profit
GrossProfit
52313000 USD
CY2019Q3 us-gaap Gross Profit
GrossProfit
52327000 USD
CY2019Q4 us-gaap Gross Profit
GrossProfit
54335000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2087000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
9895000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
10759000 USD
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
4243000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-612000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
11526000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
100423000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
4216000 USD
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.88
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.84
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2018Q1 us-gaap Revenues
Revenues
43592000 USD
CY2018Q2 us-gaap Revenues
Revenues
47350000 USD
CY2018Q3 us-gaap Revenues
Revenues
49135000 USD
CY2018Q4 us-gaap Revenues
Revenues
53041000 USD
CY2018Q1 us-gaap Gross Profit
GrossProfit
38680000 USD
CY2018Q2 us-gaap Gross Profit
GrossProfit
41739000 USD
CY2018Q3 us-gaap Gross Profit
GrossProfit
43670000 USD
CY2018Q4 us-gaap Gross Profit
GrossProfit
46994000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
2442000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3913000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
6233000 USD
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
9150000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
3066000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
4611000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
7171000 USD
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
10360000 USD
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19

Files In Submission

Name View Source Status
0001347178-20-000003-index-headers.html Edgar Link pending
0001347178-20-000003-index.html Edgar Link pending
0001347178-20-000003.txt Edgar Link pending
0001347178-20-000003-xbrl.zip Edgar Link pending
fanapt.gif Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hetlioz.gif Edgar Link pending
MetaLinks.json Edgar Link pending
partiiitem5chart.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
researchanddevelopment.jpg Edgar Link pending
Show.js Edgar Link pending
vnda-20191231.xsd Edgar Link pending
vnda-20191231_cal.xml Edgar Link unprocessable
vnda-20191231_def.xml Edgar Link unprocessable
vnda-20191231_lab.xml Edgar Link unprocessable
vnda-20191231_pre.xml Edgar Link unprocessable
vnda1231201910k.htm Edgar Link pending
vnda1231201910k_htm.xml Edgar Link completed
vnda12312019ex231.htm Edgar Link pending
vnda12312019ex311.htm Edgar Link pending
vnda12312019ex312.htm Edgar Link pending
vnda12312019ex321.htm Edgar Link pending